Sulphasalazine has been shown to have specific antirheumatoid activity. [1] [2] [3] [4] [5] [6] The mechanism of action of sulphasalazine in rheumatoid arthritis (RA) is unknown, but there is evidence from two independent studies that sulphapyridine (SP), the sulphonamide component of the sulphasalazine molecule, is the active agent.7 x In addition, 5-aminosalicylic acid, the salicylate moiety of sulphasalazine, does not display second line activity in RA.9 If SP is effective in treating RA through its antimicrobial properties it may be expected that other sulphonamides with a similar antimicrobial spectrum of activity may also have antirheumatoid properties, provided that they are accessible to the same site or sites of action as SP. Sulphamethoxazole is such a drug.
In 
DISEASE ACTIVITY
Changes in disease activity durin treatment were determined by regression analysis 4 because of the high number of patients withdrawing from the trial.
Of the patients completing a minimum of eight weeks' treatmenit with CTZ, the only significant improvement in disease activity was in serum immunoglobulins, IgM falling from a median of 280 IU/I at week 0 to 130 IU/I at week 24 (p<0-005). There was a deterioration in disease activity as judged by increases in articular index, early morning stiffness, proximal interphalangeal joint circumference, and plasma viscosity, and a fall in grip strength, but only the increase in articular index reached statistical significance (Table 3) . None of the patients actually felt that CTZ had improved their condition, and no patient elected to remain on the drug at the end of the study.
There was no significant difference in the disease activity or age of patients before onset of treatment with CTZ or SP (Mann-Whitney U test). In contrast with patients treated with CTZ, there was an improvement in disease activity in patients during treatment with SP (Table 3) .
STEADY STATE CONCENTRATIONS
There was a 10-fold interpatient variation in steady state serum SM concentrations, and a threefold variation in serum AcSM concentrations. The mean steady state circulating concentration of free sulphonamides was considerably greater than that found in the group of patients treated with SP (Table 2) .
There was no correlation between serum concentrations of SM or AcSM and the incidence of side effects.
Discussion
All sulphonamides are structural analogues of paminobenzoic acid, required by certain bacteria as a precursor for the synthesis of folic acid. They compete with p-aminobenzoic acid for the enzyme dihydropteroate synthetase and hence inhibit folic acid production. They may also become incorporated into the folate molecule in place of paminobenzoic acid, forming a 'false folate', interfering in subsequent reactions with folic acid. The pamino (N4) group greater than that used in this study (2 g/day compared with 1-2 g/day).
A dose of this magnitude may be therapeutically effective in RA, but many of his patients developed hepatotoxicity, not seen with the more moderate dosage regimen used in our study. If the higher dose of SM has second line activity in RA, this suggests the risk/benefit ratio of SM in RA is very close, and will limit the use of the drug in this disease.
The antibacterial activity of the sulphonamides is dependent on the pH of the environment, the electrochemical properties of the N, substituted radical, and the acid dissociation constant Exacerbations of RA may result from microbial stimuli within the gut. The progression of the disease may then be enhanced by the release of bacterial toxins which act by activation of cell membrane phospholipase, inducing synthesis of leucotrienes, prostaglandins, and thromboxanes. Further clarification of the mechanism of action of SP in RA within the gut may come either from a trial of a 'non-absorbable' sulphonamide with a pKa >7, or from the use of a colonic release preparation of a non-sulphonamide antibiotic with an antimicrobial spectrum similar to that of the sulphonamides. 
